WO2008111497A1 - トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 - Google Patents
トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 Download PDFInfo
- Publication number
- WO2008111497A1 WO2008111497A1 PCT/JP2008/054119 JP2008054119W WO2008111497A1 WO 2008111497 A1 WO2008111497 A1 WO 2008111497A1 JP 2008054119 W JP2008054119 W JP 2008054119W WO 2008111497 A1 WO2008111497 A1 WO 2008111497A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agent
- prophylactic
- oxidative stress
- retinal
- disease associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本発明は、酸化ストレスが関連する眼疾患の新たな予防又は治療剤を提供する。下記一般式(I)で表される化合物又はその塩は、神経網膜、網膜色素上皮、網脈絡膜といった後眼部組織において、優れた異物代謝系第2相酵素の誘導能を発揮するので、加齢黄斑変性、糖尿病網膜症、糖尿病黄斑浮腫、網膜色素変性症、増殖性硝子体網膜症、網膜動脈閉塞症、網膜静脈閉塞症、ぶどう膜炎、レーベル病、未熟児網膜症、網膜剥離、網膜色素上皮剥離、これらの疾患に起因する視神経障害、緑内障に起因する視神経障害、虚血性視神経障害、白内障などの酸化ストレスが関連する眼疾患の予防又は治療剤として有用である。 【化1】
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007058764 | 2007-03-08 | ||
JP2007-058764 | 2007-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008111497A1 true WO2008111497A1 (ja) | 2008-09-18 |
Family
ID=39759436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/054119 WO2008111497A1 (ja) | 2007-03-08 | 2008-03-07 | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2008247898A (ja) |
WO (1) | WO2008111497A1 (ja) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009089545A1 (en) * | 2008-01-11 | 2009-07-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
US7678830B2 (en) | 2002-01-15 | 2010-03-16 | Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
US7714012B2 (en) | 2006-11-17 | 2010-05-11 | Trustees Of Dartmouth University | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) |
US7795305B2 (en) | 2000-11-28 | 2010-09-14 | Board Of Regents, The University Of Texas System | CDDO-compounds and combination therapies thereof |
US7863327B2 (en) | 1998-06-19 | 2011-01-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US7915402B2 (en) | 2008-04-18 | 2011-03-29 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
US7943778B2 (en) | 2008-04-18 | 2011-05-17 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives |
WO2010093944A3 (en) * | 2009-02-13 | 2011-08-11 | Reata Pharmaceuticals, Inc. | Delayed release, oral dosage compositions that contain amorphous cddo-me |
US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
US8124799B2 (en) | 2008-04-18 | 2012-02-28 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
US8258329B2 (en) | 2008-04-18 | 2012-09-04 | Reata Pharmaceuticals, Inc. | Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use |
US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
US8314137B2 (en) | 2008-07-22 | 2012-11-20 | Trustess Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
JP2013544838A (ja) * | 2010-12-03 | 2013-12-19 | アラーガン インコーポレイテッド | 網膜の疾患を治療するための方法 |
US8921340B2 (en) | 2006-11-17 | 2014-12-30 | Trustees Of Dartmouth College | Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions |
US8993640B2 (en) | 2012-04-27 | 2015-03-31 | Reata Pharmaceuticals, Inc. | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
US9174941B2 (en) | 2010-12-17 | 2015-11-03 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
US9205113B2 (en) | 2012-05-08 | 2015-12-08 | Trustees Of Dartmouth College | Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression |
US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
US9290536B2 (en) | 2011-03-11 | 2016-03-22 | Reata Pharmaceuticals, Inc. | C4 monomethyl triterpenoid derivatives and methods of use thereof |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
US9593074B2 (en) | 2012-09-10 | 2017-03-14 | Reata Pharmaceuticals, Inc. | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
WO2017121766A1 (en) | 2016-01-12 | 2017-07-20 | Kaleyde Pharmaceuticals Ag | Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa |
US10105372B2 (en) | 2010-04-12 | 2018-10-23 | Reata Pharmaceuticals, Inc. | Methods of treating obesity using antioxidant inflammation modulators |
US10953020B2 (en) | 2016-11-08 | 2021-03-23 | Reata Pharmaceuticals, Inc. | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
US11117927B2 (en) | 2013-04-24 | 2021-09-14 | Abbvie Inc. | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
US11584775B2 (en) | 2015-09-23 | 2023-02-21 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3318264A1 (en) * | 2009-08-24 | 2018-05-09 | Stealth Peptides International, Inc. | Methods ans compositions for preventing or treating opthalmic conditions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051313A2 (en) * | 2001-12-18 | 2003-06-26 | Brassica Foundation For Chemoprotection Research, Inc. | Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
WO2005063295A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
WO2005063249A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
WO2008016095A1 (fr) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
-
2008
- 2008-03-07 JP JP2008057238A patent/JP2008247898A/ja not_active Withdrawn
- 2008-03-07 WO PCT/JP2008/054119 patent/WO2008111497A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003051313A2 (en) * | 2001-12-18 | 2003-06-26 | Brassica Foundation For Chemoprotection Research, Inc. | Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
WO2005063295A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
WO2005063249A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
WO2008016095A1 (fr) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
Non-Patent Citations (5)
Title |
---|
DINKOVA-KOSTOVA A.T. ET AL.: "Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress", PROC. NATL. ACAD. SCI. U.S.A., vol. 102, no. 12, 22 March 2005 (2005-03-22), pages 4584 - 4589, XP055117477, DOI: doi:10.1073/pnas.0500815102 * |
GAO X. ET AL.: "Induction of phase 2 genes by sulforaphane protects retinal pigment epithelial cells against photooxidative damage", PROC. NATL. ACAD. SCI. U.S.A., vol. 101, no. 28, 13 July 2004 (2004-07-13), pages 10446 - 10451, XP002993321 * |
LIBY K. ET AL.: "The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling", CANCER RES., vol. 65, no. 11, 1 June 2005 (2005-06-01), pages 4789 - 4798, XP003020927 * |
YATES M.S. ET AL.: "Pharmacodynamic characterization of chemopreventive triterpernoids as exceptionally potent inducers of Nrf2-regulated genes", MOL. CANCER THER., vol. 6, no. 1, 1 January 2007 (2007-01-01), pages 154 - 162, XP002456640 * |
YATES M.S. ET AL.: "Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-12-diooxoleana-1,9(11)-dien-28-oyl]imidazole", CANCER RES., vol. 66, no. 4, 15 February 2005 (2005-02-15), pages 2488 - 2494 * |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8034955B2 (en) | 1998-06-19 | 2011-10-11 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US8586775B2 (en) | 1998-06-19 | 2013-11-19 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US7863327B2 (en) | 1998-06-19 | 2011-01-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US7795305B2 (en) | 2000-11-28 | 2010-09-14 | Board Of Regents, The University Of Texas System | CDDO-compounds and combination therapies thereof |
US8067465B2 (en) | 2002-01-15 | 2011-11-29 | The Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
US7678830B2 (en) | 2002-01-15 | 2010-03-16 | Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
US8921340B2 (en) | 2006-11-17 | 2014-12-30 | Trustees Of Dartmouth College | Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions |
US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
US8067394B2 (en) | 2006-11-17 | 2011-11-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) |
US7714012B2 (en) | 2006-11-17 | 2010-05-11 | Trustees Of Dartmouth University | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) |
EA022166B1 (ru) * | 2008-01-11 | 2015-11-30 | Ритэ Фамэсутиклс, Инк. | Синтетические тритерпеноиды и их применение в лечении заболеваний |
AU2009203941B2 (en) * | 2008-01-11 | 2015-03-12 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids and methods of use in the treatment of disease |
US9757359B2 (en) | 2008-01-11 | 2017-09-12 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
EP3492077A1 (en) * | 2008-01-11 | 2019-06-05 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
US8129429B2 (en) | 2008-01-11 | 2012-03-06 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
WO2009089545A1 (en) * | 2008-01-11 | 2009-07-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
US8455544B2 (en) | 2008-01-11 | 2013-06-04 | Reata Pharmaecuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
US8338618B2 (en) | 2008-04-18 | 2012-12-25 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
USRE45288E1 (en) | 2008-04-18 | 2014-12-09 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
US9249089B2 (en) | 2008-04-18 | 2016-02-02 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives |
US9233998B2 (en) | 2008-04-18 | 2016-01-12 | Reata Pharmaceuticals, Inc. | Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use |
US8394967B2 (en) | 2008-04-18 | 2013-03-12 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives |
US8440820B2 (en) | 2008-04-18 | 2013-05-14 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
US8440854B2 (en) | 2008-04-18 | 2013-05-14 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
US10556858B2 (en) | 2008-04-18 | 2020-02-11 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
US11091430B2 (en) | 2008-04-18 | 2021-08-17 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
US8124656B2 (en) | 2008-04-18 | 2012-02-28 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
US10093614B2 (en) | 2008-04-18 | 2018-10-09 | Reata Pharmaceuticals, Inc. | Antioxidant Inflamation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
US8258329B2 (en) | 2008-04-18 | 2012-09-04 | Reata Pharmaceuticals, Inc. | Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use |
US8124799B2 (en) | 2008-04-18 | 2012-02-28 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
USRE45325E1 (en) | 2008-04-18 | 2015-01-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
US8071632B2 (en) | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
US9796668B2 (en) | 2008-04-18 | 2017-10-24 | Reata Pharmaceuticals, Inc. | Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use |
US7915402B2 (en) | 2008-04-18 | 2011-03-29 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
US11919838B2 (en) | 2008-04-18 | 2024-03-05 | Reata Pharmaceuticals Holdings, LLC | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
US9090574B2 (en) | 2008-04-18 | 2015-07-28 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
US9102681B2 (en) | 2008-04-18 | 2015-08-11 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
US7943778B2 (en) | 2008-04-18 | 2011-05-17 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives |
US9670147B2 (en) | 2008-04-18 | 2017-06-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
US9000188B2 (en) | 2008-07-22 | 2015-04-07 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
US8314137B2 (en) | 2008-07-22 | 2012-11-20 | Trustess Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
US9155721B2 (en) | 2009-02-13 | 2015-10-13 | Reata Pharmaceuticals, Inc. | Delayed release, oral dosage compositions that contain amorphous CDDO-Me |
EP3254675A1 (en) * | 2009-02-13 | 2017-12-13 | Reata Pharmaceuticals, Inc. | Delayed release, oral dosage compositions that contain amorphous cddo-me |
WO2010093944A3 (en) * | 2009-02-13 | 2011-08-11 | Reata Pharmaceuticals, Inc. | Delayed release, oral dosage compositions that contain amorphous cddo-me |
CN102387789A (zh) * | 2009-02-13 | 2012-03-21 | 瑞阿特制药公司 | 含有无定形cddo-me的延迟释放口服组合物 |
EA023652B1 (ru) * | 2009-02-13 | 2016-06-30 | Реата Фармасьютикалз, Инк. | Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me) |
JP2012518008A (ja) * | 2009-02-13 | 2012-08-09 | リアタ ファーマシューティカルズ,インク | 非晶質cddo−meを含有する遅延放出性経口投薬組成物 |
US8747901B2 (en) | 2009-02-13 | 2014-06-10 | Reata Pharmaceuticals, Inc. | Delayed release, oral dosage compositions that contain amorphous CDDO-Me |
CN105232471A (zh) * | 2009-02-13 | 2016-01-13 | 瑞阿特制药公司 | 含有无定形cddo-me的延迟释放口服组合物 |
US11911395B2 (en) | 2010-04-12 | 2024-02-27 | Reata Pharmaceuticals Holdings, LLC | Methods of treating obesity using antioxidant inflammation modulators |
US10105372B2 (en) | 2010-04-12 | 2018-10-23 | Reata Pharmaceuticals, Inc. | Methods of treating obesity using antioxidant inflammation modulators |
JP2013544838A (ja) * | 2010-12-03 | 2013-12-19 | アラーガン インコーポレイテッド | 網膜の疾患を治療するための方法 |
US9174941B2 (en) | 2010-12-17 | 2015-11-03 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
US9884809B2 (en) | 2010-12-17 | 2018-02-06 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
US11814338B2 (en) | 2010-12-17 | 2023-11-14 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
US11192852B2 (en) | 2010-12-17 | 2021-12-07 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
US9290536B2 (en) | 2011-03-11 | 2016-03-22 | Reata Pharmaceuticals, Inc. | C4 monomethyl triterpenoid derivatives and methods of use thereof |
US11078230B2 (en) | 2012-04-27 | 2021-08-03 | Reata Pharmaceuticals, Inc. | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
JP2015521166A (ja) * | 2012-04-27 | 2015-07-27 | リアタ ファーマシューティカルズ インコーポレイテッド | バルドキソロンメチルの2,2−ジフルオロプロピオンアミド誘導体、その多形体および使用方法 |
US8993640B2 (en) | 2012-04-27 | 2015-03-31 | Reata Pharmaceuticals, Inc. | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
US9701709B2 (en) | 2012-04-27 | 2017-07-11 | Reata Pharmaceuticals, Inc. | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
US9205113B2 (en) | 2012-05-08 | 2015-12-08 | Trustees Of Dartmouth College | Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression |
US9539287B2 (en) | 2012-05-08 | 2017-01-10 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
US10898499B2 (en) | 2012-09-10 | 2021-01-26 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
US11406648B2 (en) | 2012-09-10 | 2022-08-09 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
US9889143B2 (en) | 2012-09-10 | 2018-02-13 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
US10501489B2 (en) | 2012-09-10 | 2019-12-10 | Reata Pharmaceuticals, Inc. | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
US10398711B2 (en) | 2012-09-10 | 2019-09-03 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
US9593074B2 (en) | 2012-09-10 | 2017-03-14 | Reata Pharmaceuticals, Inc. | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
US11873320B2 (en) | 2013-04-24 | 2024-01-16 | Reata Pharmaceuticals Holdings, LLC | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
US11117927B2 (en) | 2013-04-24 | 2021-09-14 | Abbvie Inc. | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
US11584775B2 (en) | 2015-09-23 | 2023-02-21 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses |
WO2017121766A1 (en) | 2016-01-12 | 2017-07-20 | Kaleyde Pharmaceuticals Ag | Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa |
US11446313B2 (en) | 2016-11-08 | 2022-09-20 | Reata Pharmaceuticals Holdings, LLC | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
US10953020B2 (en) | 2016-11-08 | 2021-03-23 | Reata Pharmaceuticals, Inc. | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2008247898A (ja) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008111497A1 (ja) | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 | |
RU2009145939A (ru) | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза | |
Kerr et al. | Intraocular pressure during femtosecond laser pretreatment of cataract | |
JP2008538215A5 (ja) | ||
Tu | Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives | |
EP4302829A3 (en) | Peptide for use in preventing or treating macular degeneration | |
NZ588938A (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
CA2582316A1 (en) | Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases | |
WO2007075720A8 (en) | Topical mecamylamine formulations for ocular administration and uses thereof | |
WO2008019417A3 (en) | Treatment of ocular diseases | |
MX2020007948A (es) | Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular. | |
GB2432526A (en) | Use of ifenprodil for the treatment of ophthalmic diseases | |
Ellies et al. | Macular hemorrhage after laser in situ keratomileusis for high myopia | |
Helbig | Surgery for diabetic retinopathy | |
WO2021220061A3 (en) | Heterodimer compositions and methods for the treatment of ocular disorders | |
WO2019054960A3 (en) | Improving ophthalmic telomerase activity via topical and local ocular applications and preventing, delaying and / or treating impairments or diseases experienced due to degenerative processes (such as aging) | |
FI3720428T3 (fi) | Dobesiliinihappoa käsittävä oftalminen paikalliskoostumus silmän takasegmentin sairauksien hoitoon | |
JP2013513606A5 (ja) | ||
CA2453442A1 (en) | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases | |
Cheung et al. | Stabilization of anterior chamber depth during phacoemulsification cataract surgery in vitrectomized eyes | |
Yates et al. | Scleral rupture during intraoperative silicone oil injection in pars plana vitrectomy | |
Watanabe et al. | Cystoid macular edema associated with latanoprost use in a pseudophakic eye with a history of surgical complications | |
Friberg et al. | Migration of intravitreal silicone oil through a Baerveldt tube into the subconjunctival space | |
TWI766565B (zh) | 用於治療眼疾的組合物及其用途 | |
Dervenis et al. | Anterior segment approach for the surgical management of aqueous misdirection syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08721537 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08721537 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |